Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

National Institute of Environmental Health Sciences

Use this QR code to view the newest version of this document
Use this QR code to view the newest version of this document

Your Environment. Your Health.

Project Publications: University of Washington: Paraoxonases: Biomarkers of Susceptibility to Environmentally-Induced Diseases

Superfund Research Program

Paraoxonases: Biomarkers of Susceptibility to Environmentally-Induced Diseases

Project Leader: Lucio G. Costa
Grant Number: P42ES004696
Funding Period: 2000 - 2009

Project-Specific Links

Connect with the Grant Recipients

Visit the grantee's eNewsletter page Visit the grantee's eNewsletter page Visit the grantee's Facebook page Visit the grantee's Video page

Publications

2008

  • Stevens RC, Suzuki SM, Cole TB, Park SS, Richter RJ, Furlong CE. 2008. Engineered recombinant human paraoxonase 1 (rHuPON1) purified from Escherichia coli protects against organophosphate poisoning. Proc Natl Acad Sci U S A 105(35):12780-12784. doi:10.1073/pnas.0805865105 PMID:18711144 PMCID:PMC2529096

2006

  • Cole TB. 2006. Pon1 status of farmworker mothers and children as a predictor of organophosphate sensitivity. In: Washington State Pesticide Incident Reporting and Tracking (PIRT) Review Panel Meeting; May 18. Tumwater, WA.
  • Costa LG. 2006. Current issues in organophosphate toxicology. Clin Chim Acta 366(1-2):1-13. PMID:16337171
  • Costa LG, Cole TB, Furlong CE. 2006. Gene-environment interactions: paraoxonase (PON1) and sensitivity to organophosphate toxicity. LabMedicine 37(2):109-113.
  • Costa LG, Cole TB, Furlong CE. 2006. Genetic ponymorphisms of human paraoxonase (PON1) and susceptibility to organophosphorous insecticide toxicity. In: 28th International Congress on Occupational Health (ICOH); May 11-16. Milan, Italy.
  • Costa LG, Cole TB, Furlong CE. 2006. PON1 and organophosphate toxicity. In: 2nd International Conference on paraoxonases; September 7-10. Debrecen, Hungary.
  • Furlong CE, Cole TB, Richter RJ, Brophy V, Carlson CS, Rieder R, Nickerson DA, Costa LG, Ranchalis J, Jarvik GP, Lusis AJ, Shih DM, Tward A. 2006. The functional consequences of polymorphisms in the human PON1 gene. In: 2nd International Conference on paraoxonases; September 7-10. Debrecen, Hungary.
  • Kelada SN, Checkoway H, Kardia SL, Carlson CS, Costa-Mallen P, Eaton DL, Firestone JA, Powers KM, Swanson PD, Franklin GM, Longstreth WT, Smith-Weller T, Afsharinejad Z, Costa LG. 2006. 5' and 3' region variability in the dopamine transporter gene (SLC6A3), pesticide exposure and Parkinson's disease risk: a hypothesis-generating study. Hum Mol Genet 15(20):3055-3062. doi:10.1093/hmg/ddl247 PMID:16963468
  • Maraganore DM, de Andrade M, Elbaz A, Farrer MJ, Ioannidis JP, Kruger R, Rocca WA, Schneider NK, Lesnick TG, Lincoln SJ, Hulihan MM, Aasly JO, Ashizawa T, Chartier-Harlin M, Checkoway H, Ferrarese C, Hadjigeorgiou G, Hattori N, Kawakami H, Lambert J, Lynch T, Mellick GD, Papapetropoulos S, Parsian A, Quattrone A, Riess O, Tan E, Van Broeckhoven C. 2006. Collaborative analysis of {alpha}-synuclein gene promoter variability and parkinson disease. JAMA - Journal of the American Medical Association 296(6):661-670. PMID:16896109
  • Powers KM, Smith-Weller T, Franklin GM, Longstreth WT, Swanson PD, Checkoway H. 2006. Diabetes, smoking, and other medical conditions in relation to Parkinson's disease risk. Parkinsonism Relat Disord 12(3):185-189. PMID:16364673

2005

  • Cole TB, Walter BJ, Shih DM, Tward A, Lusis AJ, Timchalk C, Richter RJ, Costa LG, Furlong CE. 2005. Toxicity of chlorpyrifos and chlorpyrifos oxon in a transgenic mouse model of the human paraoxonase (PON1) Q192R polymorphism. Pharmacogenet Genomics 15(8):589-598. PMID:16007003
  • Costa LG, Cole TB, Furlong CE. 2005. Paraoxonase (PON1): from toxicology to cardiovascular medicine. Acta Biomed 76Suppl2:50-57. PMID:16353344
  • Costa LG, Cole TB, Vitalone A, Furlong CE. 2005. Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity. Clin Chim Acta 352(1-2):37-47. PMID:15653099
  • Costa LG, Vitalone A, Cole TB, Furlong CE. 2005. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 69(4):541-550. PMID:15670573
  • Furlong CE, Cole TB, Jarvik GP, Pettan-Brewer C, Geiss GK, Richter RJ, Shih DM, Tward A, Lusis AJ, Costa LG. 2005. Role of paraoxonase (PON1) status in pesticide sensitivity: genetic and temporal determinants. Neurotoxicology 26(4):651-659. PMID:16112327
  • Furlong CE, Cole TB, Walter BJ, Shih DM, Tward A, Lusis AJ, Timchalk C, Richter RJ, Costa LG. 2005. Paraoxonase 1 (PON1) status and risk of insecticide exposure. J Biochem Mol Toxicol 19(3):182-183. PMID:15977192
  • Guizzetti M, Pathak S, Giordano G, Costa LG. 2005. Effect of organophosphorus insecticides and their metabolites on astroglial cell proliferation. Toxicology 215(3):182-190. PMID:16102884
  • Kelada SN, Costa-Mallen P, Checkoway H, Carlson CS, Smith-Weller T, Swanson PD, Franklin GM, Longstreth WT, Afsharinejad Z, Costa LG. 2005. Dopamine transporter (SLC6A3) 5' region haplotypes significantly affect transcriptional activity in vitro but are not associated with Parkinson's disease. Pharmacogenet Genomics 15(9):659-668. PMID:16041244

2003

  • Cole TB, Jampsa RL, Walter BJ, Arndt TL, Richter RJ, Shih DM, Tward A, Lusis AJ, Jack RM, Costa LG, Furlong CE. 2003. Expression of human paraoxonase (PON1) during development. Pharmacogenet Genomics 13(6):357-364. PMID:12777966
  • Costa LG, Cole TB, Furlong CE. 2003. Polymorphisms of paraoxonse (PONl)and their significance in clinical toxicology of organophosphates. Toxicology 41(1):37-45. PMID:12645966
  • Costa LG, Cole TB, Jarvik GP, Furlong CE. 2003. Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med 54:371-392. doi:10.1146/annurev.med.54.101601.152421 PMID:12525679
  • Costa LG, Richter RJ, Li WE, Cole TB, Guizzetti M, Furlong CE. 2003. Paraoxonase (PON 1) as a biomarker of susceptibility for organophosphate toxicity. Biomarkers 8(1):1-12. doi:10.1080/13547500210148315 PMID:12519632
  • Kelada SN, Costa-Mallen P, Checkoway H, Viernes HA, Farin FM, Costa LG, Longstreth WT, Furlong CE, Jarvik GP, Swanson PD. 2003. Paraoxonase 1 promoter and coding region polymorphisms in Parkinson's disease. Journal of Neurology, Neurosurgery & Psychiatry 74(4):546-547. PMID:12640090

2002

  • Costa LG, Furlong CE. 2002. Perspectives in PONI research. Chapter 10. In: Paraoxonase (PON1) in Health and Disease: Basic and Clinical Aspects. Kluwer Academic Publishers, pp.197-210.
  • Costa LG, Li WF, Richter RJ, Shih DM, Lusis AJ, Furlong CE. 2002. PONl and organophosphate toxicity. Chapter 8. In: Paraoxonase (PON1) in Health and Disease: Basic and Clinical Aspects. Kluwer Academic Publishers, pp.165-183.
  • Furlong CE, Cole TB, Jarvik GP, Costa LG. 2002. Pharmacogenomic considerations of the paraoxonase polymorphisms. Pharmacogenet Genomics 3(3):341-348. PMID:12052142
  • Lu H, Guizzetti M, Costa LG. 2002. Inorganic lead activates the mitogen-activated protein kinase kinase-mitogen-activated protein kinase-p90(RSK) signaling pathway in human astrocytoma cells via a protein kinase C-dependent mechanism. J Pharmacol Exp Ther 300(3):818-823. PMID:11861786

2001

  • Costa LG. 2001. Pesticide exposure: differential risk for neurotoxic outcomes due to enzyme polymorphisms. Neurotoxicology 1(3):511-523.
  • Lu H, Guizzetti M, Costa LG. 2001. Inorganic lead stimulates DNA synthesis in human astrocytoma cells: role of protein kinase Calpha. J Neurochem 78(3):590-599. PMID:11483662
Back
to Top